{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-019505","form_type":"8-K","ticker":"IRD","cik":"0001228627","company_name":"Opus Genetics, Inc.","filed_at":"2023-04-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.196525+00:00","generated_at":"2026-06-16T21:10:20.107657+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Ocuphire Pharma terminates CEO Mina Sooch, appoints Rick Rodgers as interim CEO","bullets":["On April 19, 2023, terminated CEO Mina Sooch; Richard Rodgers appointed interim President & CEO.","Rodgers receives $40,000 monthly salary and 50,000 RSUs vesting in 12 months.","Rodgers resigned from Audit and Compensation Committees; Gallagher and Manuso filled vacancies.","Interim CEO to focus on APX3330 Phase 3 path and Nyxol NDA with PDUFA in September 2023.","Company retained executive search firm to identify a permanent CEO."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-019505","json":"https://secwatch.observer/filing/0001140361-23-019505.json","markdown":"https://secwatch.observer/filing/0001140361-23-019505.md","text":"https://secwatch.observer/filing/0001140361-23-019505.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1228627/000114036123019505/0001140361-23-019505-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1228627/000114036123019505/brhc20051717_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T21:10:20.107657+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"eb6e8fd9c3","claim":"Richard Rodgers was appointed as interim President and Chief Executive Officer at Opus Genetics, Inc..","evidence_excerpt":"On April 19, 2023, the Board of Directors o f the Company (the “ Board ”) appointed Richard Rodgers as the Company’s interim President and Chief Executive Officer effective as of April 19 , 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1228627/000114036123019505/0001140361-23-019505-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"interim President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"f3ddf43d48","claim":"Mina Sooch was terminated as President and Chief Executive Officer at Opus Genetics, Inc..","evidence_excerpt":"On April 19, 2023, Ocuphire Pharma, Inc. (the “ Company ”) terminated the employment of Mina Sooch, the President and Chief Executive Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1228627/000114036123019505/0001140361-23-019505-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}